Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today that the Phase 2a results for its broad-spectrum influenza vaccine candidate, OVX836, have been published under the title “Randomized, …
Archives de l’auteur : osivax
World Congress Vaccine Washington
Washington DC – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “Clinical Development Update on OVX836 disruptive T-cell vaccine for broad-protection against multiple influenza strains”.
Osivax Appoints Dr. Michael Watson, Former President of Moderna Vaccine Division, to its Board of Directors
Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress Lyon, France – April 14, 2022 – Osivax, a biopharmaceutical company developing vaccines to protect against highly mutating infectious diseases, announced today the appointment of Dr. Michael Watson to its Board of Directors. Dr. Watson brings over 20 years …
Vaccine Summit Boston 2022
Virtual – PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled “OVX836, a next generation universal Influenza vaccine focusing on T-Cell responses: Update on the clinical development plan”.
Covid-19 : à la recherche des vaccins de nouvelle génération
14 drug discovery startups to watch, according to top VCs
8th ESWI 2021
Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present additional efficacy endpoints of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
3rd Edition Vaccine World Asia Congress
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « A new approach towards a universal influenza vaccine: clinical update of OVX836 ».
Immunotherapies & Innovation for Infectious Diseases (I4ID)
Lyon – Oral PresentationDelphine Guyon-Gellin, Chief of Business Development of Osivax, to provide a clinical update on OVX836 as part of a presentation entitled « A new approach towards a universal influenza vaccine: clinical update of OVX836 ».
6th International Conference on Vaccine R&D
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».